Remove Biosimilars Remove Definition Remove Medication Therapy Management (MTM)
article thumbnail

CMS Issues Sweeping End-Of Year Rule on Medicare Advantage and Medicare Part D

Putting Patients First Blog

Biosimilars and Generics The formulary inclusion of biosimilars and generics is essential in reducing the costs of medications for Medicare recipients. To enable lower cost medications, CMS would require that plan formularies prioritize access to biosimilars, generics, and affordable other alternatives.

article thumbnail

NHC Submits Comments to CMS RE CY 2026 Policy & Technical Changes to MA and Part D Proposed Rule

Putting Patients First Blog

To strengthen the proposal, the NHC recommends that CMS avoid implementing rigid definitions of overweight and obese. Instead, CMS should review Part D plan prior authorization criteria to ensure that plan definitions align with treatment guidelines and ICD-10 diagnosis codes, promoting consistency and alignment among providers and payers.